Calmark Sweden AB locates Chinese mainland office to Wuxi, outside Shanghai

Calmark Sweden AB today announced that a new decision has been made regarding the location of the Company's office in mainland China. Following financial negotiations, the alternative to locate the office to Wuxi, outside Shanghai, appears more advantageous than the previously disclosed location, the Greater Bay Area.

Wuxi International Life-Science Innovation Campus (I•Campus) is about an hour away from Shanghai. It is a startup hub and was co-built by Wuxi Municipal Government, Wuxi New District Government and AstraZeneca. It offers premises and modern infrastructure to newly established businesses, mainly within life sciences and biotechnology. It is open only to companies that apply and qualify, which Calmark has done.

The local government of Wuxi offers a rent-free period of three years, and there is a possibility to be eligible for financial support for registration of products as well as a reimbursement of registration costs from the CFDA as the Company expands. Logistically and recruitment-wise, the location is equivalent to the Greater Bay Area.

"We have assessed the alternatives in China closely together with our consultants at Nordic Match, and after local negotiations, the Shanghai area and the Wuxi I•Campus is perceived as a better choice than the Greater Bay Area," says Anna Söderlund, CEO of Calmark. "We have thus changed our decision today as we have passed the I•Campus qualification process, and we are pleased about this."

Read more about the Wuxi International Life-Science Innovation Campus (I•Campus):
http://www.icampuswuxi.com/ws/front/en/index.html 

This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17:20 CET on 25 November 2020.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.